← Biohaven Pharmaceutical Holding Company Ltd. (BHVN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Pharmaceutical Preparations · market cap $2.1B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
7
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Biohaven Pharmaceutical (BHVN) is a clinical-stage pharma with 256 employees and a $2.25B market cap, running a broad pipeline spanning obesity, Parkinson's, bipolar disorder, multiple system atrophy, spinocerebellar ataxia, migraine, and solid tumors. The company carries no revenue, ~$739M in net losses in 2025, and only ~5.5 months of cash runway at current burn rates. The most important near-term read is a Phase 3 data event for BHV-7000 in bipolar disorder estimated for December 2026.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 3 · BHV-7000imp 9/10
- 2027-08-15 (est.)Phase 3 · BHV-8000imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BHV-1510 | Phase 2 | Solid Tumor |
| Taldefgrobep Alfa | Phase 3 | Obesity |
| BHV-8000 | Phase 3 | Parkinson Disease |
| BHV-7000 | Phase 3 | Bipolar Disorder |
| Verdiperstat | Phase 3 | Multiple System Atrophy |
| troriluzole | Phase 3 | Spinocerebellar Ataxias |
| BHV-2100 | Phase 2 | Migraine |
Price & technical context
3-month
-20.4%
6-month
+30.4%
12-month
-13.8%
52-wk range
$7.79–$18.11
vs 50-day MA
-9.3%
vs 200-day MA
+6.1%
Realized vol
95.7%
Max drawdown
-85.5%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BHVN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.